Biotech Values

[rkrw]

I've always thought it may make sense to have a small handful of sales reps detailing the product, educate buyers on just that.

I personally suspect that the Momenta product will actually have less batch-to-batch variation than Sanofi's product, simply because Momenta probably has a better characterization of the drug than does the originator. But the market doesn't know that, and given Lovenox is a "tricky" drug to use, I suspect a chunk of the market will be conservative about adoption of the generic.